Patents Assigned to University of Rijeka Faculty of Medicine
  • ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR)
    Publication number: 20240018257
    Abstract: The present invention provides monoclonal antibodies that recognize poliovirus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
    Type: Application
    Filed: August 15, 2023
    Publication date: January 18, 2024
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • ANTIBODIES SPECIFIC TO HUMAN T-CELL IMMUNOGLOBULIN AND ITIM DOMAIN (TIGIT)
    Publication number: 20210220472
    Abstract: Natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions comprising them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 22, 2021
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR)
    Publication number: 20210115150
    Abstract: The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 22, 2021
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
    Patent number: 10946095
    Abstract: Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 16, 2021
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., University of Rijeka Faculty of Medicine
    Inventors: Ofer Mandelboim, Noa S. Kaynan, Pinchas Tsukerman, Stipan Jonjic
  • Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same
    Patent number: 10716864
    Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 21, 2020
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer Mandelboim, Stipan Jonjic, Orit Berhani, Ariella Glasner
  • Vaccine comprising beta-herpesvirus
    Patent number: 10537621
    Abstract: The present invention relates to a beta-herpesvirus, preferably a recombinant beta-herpesvirus, wherein the beta-herpesvirus comprises at least one heterologous nucleic acid, wherein the at least one heterologous nucleic acid comprises a gene encoding a cellular ligand.
    Type: Grant
    Filed: January 31, 2016
    Date of Patent: January 21, 2020
    Assignee: UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventor: Stipan Jonjic
  • ANTIBODIES SPECIFIC TO HUMAN T-CELL IMMUNOGLOBULIN AND ITIM DOMAIN (TIGIT)
    Publication number: 20180185480
    Abstract: Provided is a natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Application
    Filed: September 1, 2016
    Publication date: July 5, 2018
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., University of Rijeka Faculty of Medicine
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC